---
layout: default
title: Zinc Gluconate
parent: 僅模型預測 (L5)
nav_order: 897
evidence_level: L5
indication_count: 10
---

# Zinc Gluconate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Zinc Gluconate: From Nutritional Supplementation to Anemia of Prematurity

## One-Sentence Summary

> Zinc gluconate is a mineral (zinc) supplement; no confirmed original approved indication is on file for this product in the current dataset, and it is not currently marketed in this jurisdiction.
> The TxGNN model predicts it may be effective for **Anemia of Prematurity**,
> but this prediction is currently supported by **no clinical trials** and **no publications** — it is a purely computational (L5) hypothesis.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No data available (drug not marketed; no approved indication on record) |
| Predicted New Indication | Anemia of Prematurity |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for zinc gluconate is not available in the evidence pack, and no original approved indication is on file (the product is not currently marketed in this jurisdiction). Based on general pharmacological knowledge, zinc gluconate is a mineral salt used to supplement zinc, an essential trace element that serves as a cofactor for more than 300 enzymes, including superoxide dismutase (antioxidant defense) and various enzymes involved in cell division, immune function, and wound healing.

The TxGNN model's top-ranked prediction links zinc gluconate to anemia of prematurity (score 99.94%, rank 1573). The rationale offered in the underlying evidence review is that zinc deficiency has a recognized general association with certain anemias, since zinc is a cofactor for hematopoietic enzymes. However, anemia of prematurity is a distinct clinical entity primarily driven by insufficient endogenous erythropoietin (EPO) production and depleted iron stores in preterm infants — mechanisms not directly addressed by zinc supplementation.

As a result, the mechanistic link between zinc gluconate and anemia of prematurity is assessed as weak, and — consistent with this — no clinical trials or published literature currently support this specific indication. This prediction should be treated as a computational hypothesis only, not as a basis for clinical action.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## India Market Information

Zinc gluconate currently has no marketing authorization on record in this jurisdiction (0 registrations; market status: not marketed). No license-level product data is available.

---

## Safety Considerations

**Drug Interactions**: The evidence pack lists 103 documented drug-drug interactions for zinc gluconate. Most are classified as Minor (e.g., co-administration with biologic immunomodulators such as abatacept, adalimumab, anakinra). Several **Moderate**-level interactions follow a known chelation mechanism that reduces oral bioavailability of the interacting drug:
- Bisphosphonates: alendronic acid, risedronic acid, ibandronate
- Tetracycline
- Baloxavir marboxil

These interactions generally warrant separating administration times rather than avoiding co-use entirely.

*Key warnings and contraindications are not available in the current dataset — please refer to the official product label once available.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (anemia of prematurity) has an Evidence Level of L5 — no supporting clinical trials or literature — and the proposed mechanistic rationale is weak, since anemia of prematurity is primarily an EPO/iron-driven condition rather than a zinc-deficiency disorder. Core safety data (product label warnings and contraindications) is also flagged as a **Blocking** data gap, precluding entry into a preliminary safety assessment (S1).

**To proceed, the following is needed:**
- Official product label warnings and contraindications (Blocking data gap, DG001 — TFDA label PDF retrieval/parsing)
- Mechanism of action (MOA) data from DrugBank (High-priority data gap, DG002)
- Confirmed original approved indication and regulatory history for this product
- Preclinical or mechanistic evidence directly linking zinc supplementation to erythropoiesis in preterm infants, before any further clinical evaluation is considered
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

